Objective: To compare the effects of sildenafil and sublingual (sl) apomorphine on nocturnal erections.
Methods: In a prospective, single-blinded, placebo-controlled at-home study we compared the effect of apomorphine sl and sildenafil on sleep-related erectile activity in 30 healthy potent volunteers (mean age, 26.4 years; range, 23-35 years; Erectile Function domain of the International Index of Erectile Function > or =26), not reporting any subjective sleep abnormality during 4 consecutive nights with rigidity monitoring (NPTR) with the RigiScantrade mark device. After the first night of adaptation, they were randomized to receive placebo or apomorphine sl 2mg or sildenafil 50mg taken at bedtime during the following 3 consecutive nights.
Results: Sildenafil increased the mean+/-SE number of erections, overall length of erectile events, and the time of erections with rigidity >60% at both tip and base, as compared to placebo. The same parameters were reduced after administration of apomorphine sl. Similar findings were observed with regards to Rigidity Activity Units and Tumescence Activity Units.
Conclusions: Our results confirm that sildenafil taken at bedtime might increase nocturnal erectile activity also in young potent men as compared to placebo. Apomorphine sl taken at bedtime seems to have the opposite effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2004.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * Data was collected from 37 patients treated between 2011 and 2022, highlighting that half started nocturnal treatment for motor issues, while others suffered from various non-motor symptoms.
- * The findings show 54% of patients maintained treatment by the end, with some discontinuing due to adverse reactions, indicating the treatment's overall effectiveness and safety despite some challenges.
Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
Mov Disord Clin Pract
September 2023
Movement Disorders Section Fleni, CONICET Buenos Aires Argentina.
Background: Continuous subcutaneous apomorphine infusion (CSAI) is one of the advanced therapies for Parkinson's disease (PD).
Methods: A systematic review of all published articles in English on CSAI for PD till January 30, 2022 was conducted.
Results: A total of 82 articles met the search criteria.
Perspectives on the urological care in Parkinson's disease patients.
Arch Ital Urol Androl
March 2022
Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris.
Parkinson's disease (PD) is recognized as the most common neurodegenerative disorder after Alzheimer's disease. Lower urinary tract symptoms are common in patients with PD, either storage symptoms (overactive bladder symptoms or OAB) or voiding symptoms. The most important diagnostic clues for urinary disturbances are provided by the patient's medical history.
View Article and Find Full Text PDFInvestigation of apomorphine during sleep in Parkinson's: Improvement in UPDRS Scores.
Neurol Int
November 2019
Department of Neurology, FIDES Center, Jujuy, Argentina.
Sleep is responsible for several functions required for homeostasis. REM sleep could be a rearrangement period where limits of certain functions can be moved to a new state of balance. This study proposes that dopaminergic deficit may be responsible for the circadian dysregulation that occur with neurodegeneration and therefore a restitution of REM sleep and an improvement in Parkinson disease's symptoms can be achieved with the controlled use of dopamine agonists during the night.
View Article and Find Full Text PDFQuantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
Parkinsonism Relat Disord
December 2016
The Maurice Wohl Clinical Neuroscience Institute, King's College London and National Parkinson Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Background: Nocturnal hypokinesia/akinesia is one of the common night-time symptoms in patients with Parkinson's disease (PD), negatively affecting quality of life of patients and caregivers. The recognition of this problem and treatment options are limited in clinical practice.
Objectives: To evaluate the efficacy of nocturnal apomorphine infusion, using a wearable sensor, in patients who are already on daytime continuous subcutaneous apomorphine infusion and still suffer from nocturnal hypokinesia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!